Guggenheim Capital LLC Has $5.21 Million Stake in Natera, Inc. (NASDAQ:NTRA)

Guggenheim Capital LLC reduced its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 21.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,917 shares of the medical research company’s stock after selling 9,250 shares during the quarter. Guggenheim Capital LLC’s holdings in Natera were worth $5,211,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. lifted its holdings in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc raised its stake in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after acquiring an additional 261 shares in the last quarter. Principal Securities Inc. grew its position in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after acquiring an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its holdings in Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 332 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Insider Activity

In other Natera news, Director Gail Boxer Marcus sold 4,000 shares of the stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $140.78, for a total transaction of $563,120.00. Following the completion of the transaction, the director now owns 9,704 shares in the company, valued at approximately $1,366,129.12. This represents a 29.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John Fesko sold 663 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now owns 156,044 shares in the company, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 325,922 shares of company stock worth $51,603,664 over the last quarter. 7.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on NTRA shares. Canaccord Genuity Group restated a “buy” rating and issued a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Guggenheim boosted their target price on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. Piper Sandler increased their price target on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Royal Bank of Canada assumed coverage on Natera in a report on Thursday, March 13th. They set an “outperform” rating and a $251.00 price objective on the stock. Finally, Barclays dropped their target price on Natera from $200.00 to $160.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $175.76.

Natera Price Performance

Shares of NTRA stock opened at $148.08 on Friday. The firm has a market capitalization of $20.02 billion, a price-to-earnings ratio of -84.14 and a beta of 1.80. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average of $150.68 and a 200-day moving average of $152.53.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. On average, equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.